Table 1. Studies included in the Cochrane review 2017[15] - listing researchers, intervention and duration, outcome measures and age at assessment.

Researcher and (y)	Intervention	Sample (n)	Duration	Outcome measure	Age at assessment (* indicates beneficial effect in vision or cognition)
Agostoni 1995 [64]	DHA (0.3%) and AA (0.44%)	60	4 months	Neurodevelopment (Brunet-Lezine test)	4, 12 and 24 months *
Auestad 1997 [65]	DHA (0.13%) and AA (0.45%) DHA alone (0.2%)	134	4 months exclusive and milk for 12months	Growth Visual function (VEP, Teller Cards) Neurodevelopment (BSID, Stanford-Binet IQ) Language (McArthur Communicative Development Inventory	Growth at 1, 2, 4, 6, 9 and 12 months. Visual acuity at 2, 4, 6, 9, 12 and 39 months. Neurodevelopment at 1 and 3 years. Language development at 14 months and 3 years
Auestad 2001 [66]	DHA (0.13%) and AA (0.45%	404	4 months exclusive and milk for 12 months	Visual function (VEP, Teller Cards) Neurodevelopment (BSID) Language (McArthur Communicative Development Inventory)	Growth at 1, 2, 4, 6, 9 and 12 months. Visual acuity at 2, 4, 6 and 12 months. Fagan test of infant intelligence at 6 and 9 months, Infant Development at 6 and 12 months. Language development at 9 and 14 months. Parental reporting of infant temperament at 6 and 12 months
Ben 2004 [67]	LCPUFA content of the formula was not clear.	121	to 6 months of age	Growth Neurodevelopment	Growth and neurodevelopmental outcomes at 3 and 6 months of age
Birch 1998 [68]	DHA (0.36%) and AA (0.72%).	79	until 17 weeks of age	Growth Visual function (VEP) Neurodevelopment (BSID)	Growth and visual acuity at 6, 17, 26, 39 and 52 weeks. Infant development at 18 months *
Birch 2005 [69]	DHA (0.36%) and AA (0.72%)	103	to 52 weeks of age	Growth Visual function (VEP)	Growth, and visual acuity at 6, 17, 26, 39 and 52 weeks.*
Birch 2010 [70]	DHA (0.32%) and AA (0.64%). 4 groups: control (0% DHA), 0.32% DHA, 0.64% DHA, 0.96% DHA. For Cochrane review, the 0.32% DHA chosen as the intervention arm.	170	to 1 year of age	Growth Visual function (VEP) Cognitive function, Attention control	Visual acuity at 12 months. Quality of attention, heart rate, age-appropriate standardised and specific cognitive tests (18 months to 6 years every 6-monthly), growth until 6 years of age, school readiness and receptive vocabulary. *

Bouwstra 2005 [71]	DHA (0.3%) and AA (0.45%)	315	2 months	Growth Neurodevelopment (Hempel and BSID) Growth	Neurodevelopmental assessment and growth, cardiovascular, cognitive, and behavioural assessments at 9 years
Carlson 1996 [72]	DHA (0.10%) and AA (0.43%).	39	1 year	Visual function (Teller Cards)	Visual acuity at 2, 4, 6, 9 and 12 months *
Lapillone 2000 [73]	DHA (0.31%).	24	4 months	Growth	Weight, length and head circumference at 2 and 4 months of age
Lucas 1999 [74]	DHA (0.32%) and AA (0.30%)	309	6 months	Growth Neurodevelopment (BSID) Gastrointestinal tolerance	Neurodevelopment at 18 months Growth and gastrointestinal tolerance at 6, 9 and 18 months.
Makrides 1995 [75]	DHA (0.35%)	32	to 30 weeks of life	Visual function (VEP) Neuro-development	Vision at 16 and 30 weeks *
Makrides 1999 [76]	DHA (0.34%) and AA (0.34%) DHA alone (0.34%)	83	4 months.	Growth, Neurodevelopment (BSID), Visual function (VEP)	Growth at 6, 16 and 34 weeks and at 1 and 2 years of age. Neurodevelopment at 1 and 2 years.
Morris 2000 [77]	DHA (0.2%) and AA (0.4%).	109	12 weeks	Growth	Growth at 6 weeks, 3 months, 6 months and 1 year
Willatts 1998 [78]	DHA (0.15% to 0.25%) and AA (0.3% to 0.4%).	72	4 months	Cognitive function Intelligence	Infant cognition by a means-end problem-solving test at 10 months. Assessments of intelligence quotient (IQ), attention control (Day-Night Test) and speed of processing on Matching Familiar Figures Test (MFFT) at 6 years infants *